Pharmacokinetic enhancement of protease inhibitor therapy

Keyphrases

• Ritonavir 100%
• Protease Inhibitor Therapy 100%
• Pharmacokinetic Boosting 100%
• Protease Inhibitors 66%
• Proteinase Inhibitor 66%
• Dual Protein 50%
• Saquinavir 50%
• Inhibitor Therapy 33%
• Combination Regimen 33%
• Lopinavir 33%
• Cmin 33%
• Plasma Concentration 16%
• Clinical Data 16%
• Healthy Volunteers 16%
• Antiretroviral 16%
• Metabolism 16%
• Food Restriction 16%
• Standard of Care 16%
• Clinical Benefit 16%
• Viral Replication 16%
• EC50 16%
• Absorption Mechanism 16%
• IC50 16%
• Pharmacokinetic Parameters 16%
• Cytochrome P450 Enzymes 16%
• Area under the Concentration-time Curve 16%
• Treatment of HIV Infection 16%
• Maximal Effect 16%
• Pharmacokinetic Data 16%
• Enzyme Inhibitors 16%
• Combined Antiretroviral Therapy (cART) 16%
• Antiviral Resistance 16%
• Pharmacological Properties 16%
• Resistance Increase 16%
• Antiretroviral Resistance 16%
• Metabolism Process 16%
• Plasma Trough Concentration 16%
• Pill Burden 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ritonavir 100%
• Proteinase Inhibitor 100%
• Pharmacokinetics 100%
• Protein Inhibitor 66%
• Saquinavir 50%
• Cmin 33%
• Normal Human 16%
• HIV 16%
• Pharmacokinetic Parameter 16%
• Cytochrome P450 Inhibitor 16%
• Side Effect 16%
• Human Immunodeficiency Virus Infection 16%
• Lopinavir 16%
• Virus Resistance 16%
• Lopinavir Plus Ritonavir 16%
• IC50 16%
• EC50 16%